Addex Therapeutics

If a drug were approved in focused indications such as substance‑use disorders or chronic cough subpopulations, pricing leverage could be meaningful. However, Addex has no approved products, no recurring revenue, and its leading external asset (Indivior’s GABAB PAM) is controlled by the partner.

Dipraglurant’s repositioning targets post‑stroke or TBI recovery, an area with unmet need but uncertain payer dynamics and endpoints. With today’s portfolio maturity, observed pricing power is effectively zero and remains purely hypothetical pending clinical success.